Inven2 is an efficient innovation company that turns high tech Norwegian science into sustainable business. In 2011, Inven2 had an output of 27 license agreements and establishment of one promising start-up company, Ultimovacs, a cancer vaccine company. In addition, Inven2 negotiates contracts for clinical trials of pharmaceuticals to be run at the Oslo University Hospital, a hot spot for Oslo based hospitals with a unique patient recruitment potential.
Creative Norwegian Science
Ideas are created by excellent and up-coming scientific groups at the University of Oslo, the Oslo University Hospital and other hospitals in the South-Eastern Health Region, then assessed for novelty and market potential by Inven2. If the idea has market potential, the next step is to make a plan for proof-of-principle studies. Once the principle is proven, Inven2 makes the right connections to the right business partner for a licensing opportunity or generate a business plan for a start-up company.
Much More than Fish and Oil
Seventy percent of the output is currently in the field of Life Sciences; Biotech, Pharma and similar. These are projects that need investment in attention and cash. A gradually increasing segment is IT and hardware projects, with start-up company examples like AIMS Innovation that has created a “learning” and pro-active software to prevent computer disasters.
Norwegian Infrastructure is Great for Global Business
Inven2 is based in Forskningsparken, in the heart of the Hospital and University region of Oslo. Our skills span from in-depth scientific understanding through financial, IP and legal excellence to top notch business developers with a large, global network. Inven2 has made successful connections to companies and partners in all corners of the world, and continues to expand the number in each region.
Follow us on www.inven2.com